Update: Eevia Health Reverses Eye-Health IP Transaction
Referring to the press release on February 5, 2025, Eevia Health Plc ("Eevia" or "The Company") Board has decided to cancel the agreement to sell intellectual property (IP) related to its lead eye-health compound to Havu Health Oy for KEUR 800 subject to non-conformance with conditions for sale. The IP is retracted back.
Eevia has decided to cancel the agreement to sell intellectual property (IP) related to its lead eye-health compound to Havu Health Oy for KEUR 800 subject to non-conformance with conditions for sale. The IP is clawed back. The condition was that Havu Health would either pay for the IP or convert the payable into shares in Havu Health Oy, making Eevia Health the dominant owner. Either did not materialize. The sale of the intellectual property is therefore cancelled and the IP clawed back to Eevia ownership again.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
This disclosure contains information that EEVIA HEALTH PLC must make public according to the EU Market Abuse Regulation (EU nr 596/2014). The information was originally submitted for publication through the contact person's agency on August 21, 2025, at 15:05 EEST.
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.
Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.